Summary & Overview
CPT 90471: Live Attenuated Vaccine Administration
CPT code 90471 denotes the administration of a live attenuated vaccine by percutaneous, intradermal, subcutaneous, or intramuscular routes. As a standardized procedural code, it enables consistent reporting of vaccine administration across outpatient and ambulatory care settings. Accurate use of this code affects clinical documentation, claims processing, and public health reporting for immunization delivery nationally.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for live attenuated vaccine administration, typical sites of service where 90471 is used, and which payer types commonly reimburse such services. The publication outlines benchmark considerations for vaccine administration coding, common modifier interactions (listed separately), and operational details relevant to billing staff and practice managers.
This briefing is aimed at coding professionals, revenue cycle staff, clinicians involved in immunization delivery, and payers responsible for policy. It summarizes when 90471 applies, highlights billing implications for ambulatory settings, and identifies areas where coding clarity supports accurate reimbursement and immunization tracking. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 90471 describes the administration of a live attenuated vaccine delivered by percutaneous, intradermal, subcutaneous, or intramuscular route. The procedure covers the act of giving the vaccine to a patient by one of these injection or placement techniques.
Service type: Vaccine administration
Typical site of service: Outpatient clinic, physician office, community health center, pharmacy-based clinic, or other ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A healthy adult patient presents to a primary care clinic for routine preventive care and requests influenza and tetanus-diphtheria booster vaccines. The clinician reviews immunization history, confirms vaccine indications and allergies, obtains verbal consent, and documents lot numbers and expiration dates. The provider administers live attenuated intranasal influenza vaccine via percutaneous/intranasal route or a subcutaneous/intramuscular live attenuated vaccine as indicated, observes the patient for 15 minutes for immediate adverse reaction, and records the administration in the medical record and immunization registry. The typical workflow includes patient check-in, screening for contraindications, vaccine preparation, administration using 90471, post-vaccination observation, and documentation of the vaccine product, lot, manufacturer, site, route, and any immediate adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a clinician performs a qualifying E/M visit in addition to vaccine administration |
59 |